Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK JAFFE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1730160615
CMS profile
78924
Location
HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,880.88

88 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,685.00 2
Food and Beverage $1,195.88 86

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $1,289.59 14
Janssen Biotech, Inc. $905.93 33
Horizon Therapeutics plc $179.16 16
AbbVie Inc. $110.93 5
E.R. Squibb & Sons, L.L.C. $90.68 5
PFIZER INC. $89.69 4
Mallinckrodt Hospital Products Inc. $54.96 2
Lilly USA, LLC $44.23 2
AstraZeneca Pharmaceuticals LP $44.14 3
Aurinia Pharma U.S., Inc. $40.92 2
Eisai Inc. $15.65 1
UCB, Inc. $15.00 1

Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK JAFFE

NPI 1730160615 · CMS profile ID 78924

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HOLLYWOOD, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730160615?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK JAFFE, NPI 1730160615, CMS profile ID 78924. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730160615?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARK JAFFE, NPI 1730160615, CMS profile ID 78924. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730160615?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARK JAFFE, NPI 1730160615, CMS profile ID 78924, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–88 of 88 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1730160615?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

88 matching records · $2,880.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 88 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–88 of 88.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.1806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832733217 CMS
Janssen Biotech, Inc. $3.3806/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616945 CMS
Janssen Biotech, Inc. $4.3306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616989 CMS
AstraZeneca Pharmaceuticals LP $12.5506/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829512149 CMS
Horizon Therapeutics plc $4.9806/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797152769 CMS
AbbVie Inc. $24.5906/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794939029 CMS
Amgen Inc. $16.1005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591147 CMS
Amgen Inc. $15.7905/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591119 CMS
Janssen Biotech, Inc. $5.5005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616955 CMS
Janssen Biotech, Inc. $6.4005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616975 CMS
Mallinckrodt Hospital Products Inc. $21.4205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845361309 CMS
Horizon Therapeutics plc $19.7205/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797152765 CMS
Horizon Therapeutics plc $3.9405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797152767 CMS
Janssen Biotech, Inc. $1.8405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616973 CMS
E.R. Squibb & Sons, L.L.C. $20.1505/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783491775 CMS
Janssen Biotech, Inc. $27.0804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616983 CMS
PFIZER INC. $19.4704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832686807 CMS
Janssen Biotech, Inc. $6.4804/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788617009 CMS
AbbVie Inc. $20.5604/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794939025 CMS
Amgen Inc. $4.7204/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591159 CMS
Janssen Biotech, Inc. $6.7504/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788617007 CMS
Horizon Therapeutics plc $4.8104/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797152761 CMS
Horizon Therapeutics plc $24.9104/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797152763 CMS
Janssen Biotech, Inc. $7.4403/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616953 CMS
Janssen Biotech, Inc. $9.7403/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616981 CMS
Janssen Biotech, Inc. $4.7303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616951 CMS
Janssen Biotech, Inc. $10.9103/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788616949 CMS
Lilly USA, LLC $26.9703/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818666117 CMS
Amgen Inc. $2.5003/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591143 CMS
E.R. Squibb & Sons, L.L.C. $14.5803/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783491761 CMS
Amgen Inc. $21.0303/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591139 CMS
Amgen Inc. $16.6602/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591163 CMS
AbbVie Inc. $23.2702/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794939021 CMS
E.R. Squibb & Sons, L.L.C. $17.7601/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783491759 CMS
Mallinckrodt Hospital Products Inc. $33.5401/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845361307 CMS
AbbVie Inc. $24.5901/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794939017 CMS
Amgen Inc. $5.0001/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825591155 CMS
Eisai Inc. $15.6501/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817803385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,346.55 87
PY2020 $1,738.21 53
PY2021 $2,880.88 88
PY2022 $2,859.38 126
PY2023 $1,998.69 123
PY2024 $2,657.18 119
PY2025 $1,251.64 80

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $382,214.48 44
PY2024 Principal investigator $168,150.39 31
PY2023 Principal investigator $82,355.96 24
PY2022 Principal investigator $97,710.81 48
PY2021 Principal investigator $70,502.35 28
PY2020 Principal investigator $7,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $307.08 12/31/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) No dispute reported 06/30/2026 1202535087
Principal investigator 1 Eli Lilly and Company $4,443.95 12/23/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,530.94 12/17/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289772
Principal investigator 1 ABBVIE INC. $8,719.31 12/04/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526712
Principal investigator 1 ABBVIE INC. $18,300.92 11/05/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202521553
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,866.57 10/23/2025 Non-covered Recipient Entity
GNP RESEARCH
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190311919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,000.00 10/08/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/08/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,200.00 10/08/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286557
Principal investigator 1 GlaxoSmithKline, LLC. $11,291.25 09/16/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122574
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $82,630.95 09/12/2025 Non-covered Recipient Entity
Gnp Research
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235997077
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $25,588.00 09/05/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336111
Principal investigator 1 ABBVIE INC. $3,963.92 09/04/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202508584
Principal investigator 1 ABBVIE INC. $5,300.00 08/06/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202503577
Principal investigator 1 ABBVIE INC. $19,775.00 07/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494531
Principal investigator 1 ABBVIE INC. $2,200.00 07/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494533
Principal investigator 1 ABBVIE INC. $2,200.00 07/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494535
Principal investigator 1 ABBVIE INC. $19,900.00 07/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494537
Principal investigator 1 GlaxoSmithKline, LLC. $67.50 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118405
Principal investigator 1 GlaxoSmithKline, LLC. $70.20 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118418
Principal investigator 1 GlaxoSmithKline, LLC. $290.25 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118429
Principal investigator 1 GlaxoSmithKline, LLC. $240.00 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118435
Principal investigator 1 GlaxoSmithKline, LLC. $80.00 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118441
Principal investigator 1 GlaxoSmithKline, LLC. $114.75 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122589
Principal investigator 1 GlaxoSmithKline, LLC. $290.25 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122594
Principal investigator 1 GlaxoSmithKline, LLC. $1,039.50 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122601
Principal investigator 1 GlaxoSmithKline, LLC. $101.25 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122607
Principal investigator 1 GlaxoSmithKline, LLC. $317.25 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122613
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 06/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122621
Principal investigator 1 GlaxoSmithKline, LLC. $440.00 06/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118399
Principal investigator 1 GlaxoSmithKline, LLC. $290.25 06/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118412
Principal investigator 1 GlaxoSmithKline, LLC. $864.00 06/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192118425
Principal investigator 1 GlaxoSmithKline, LLC. $1,498.50 06/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122568
Principal investigator 1 GlaxoSmithKline, LLC. $118.80 06/02/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192172575
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 05/12/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175418656
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $23,417.55 05/09/2025 Non-covered Recipient Entity
Denver Arthritis Clinic
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235997730
Principal investigator 1 Janssen Research & Development, LLC $250.00 04/07/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175418642
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 03/31/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175418636
Principal investigator 1 Janssen Research & Development, LLC $4,290.00 03/27/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1175418649
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,809.30 03/10/2025 Non-covered Recipient Entity
GNP RESEARCH
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190310516
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,497.48 02/10/2025 Non-covered Recipient Entity
GNP RESEARCH
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190310520
Principal investigator 1 GlaxoSmithKline, LLC. $2,599.50 01/28/2025 Non-covered Recipient Entity
GNP CONSULTANTS LLC
A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI No dispute reported 06/30/2026 1192122582
Principal investigator 1 Novartis Pharmaceuticals Corporation $897.96 01/09/2025 Non-covered Recipient Entity
GNP RESEARCH
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190310518
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,802.30 01/01/2025 Non-covered Recipient Entity
GNP RESEARCH
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190310522